胰腺导管腺癌肺转移的外科治疗：12例研究
Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases.
作者信息
Yasukawa Motoaki, Kawaguchi Takeshi, Kawai Norikazu, Tojo Takashi, Taniguchi Shigeki
机构信息
Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan
Department of Thoracic and Cardiovascular Surgery, Nara Medical University School of Medicine, Kashihara, Japan.
出版信息
Anticancer Res. 2017 Oct;37(10):5573-5576. doi: 10.21873/anticanres.11990.
BACKGROUND/AIM: Few studies have reported results with pulmonary metastasectomy for pancreatic ductal adenocarcinoma (PDAC), probably because of their extremely poor outcomes. The aim of this study was to review our institutional experience and analyze the outcomes of pulmonary metastasectomy for PDAC.
PATIENTS AND METHODS
A retrospective case-control study of patients undergoing pulmonary metastasectomy for isolated lung metastasis of PDAC between 2004 and 2016. Clinicopathological features were analyzed and survival curves were plotted using the Kaplan-Meier method.
RESULTS
Twelve patients were included. The median follow-up period after metastasectomy was 33 months. At the time of analysis, five patients had deceased, two were alive with disease, and five were alive without disease. The median survival time after pulmonary metastasectomy was 47 months. The estimated 3- and 5-year overall survival rates were 62.3% (95%CI=27.8-84.0) and 31.2% (95%CI=1.7-71.7).
CONCLUSION
Outcomes were favorable following pulmonary metastasectomy in selected patients with PDAC.
背景/目的：很少有研究报道胰腺导管腺癌（PDAC）肺转移瘤切除术的结果，可能是因为其预后极差。本研究的目的是回顾我们机构的经验，并分析PDAC肺转移瘤切除术的结果。
患者与方法
对2004年至2016年间因PDAC孤立性肺转移而接受肺转移瘤切除术的患者进行回顾性病例对照研究。分析临床病理特征，并采用Kaplan-Meier法绘制生存曲线。
结果
纳入12例患者。转移瘤切除术后的中位随访期为33个月。在分析时，5例患者已死亡，2例带瘤生存，5例无瘤生存。肺转移瘤切除术后的中位生存时间为47个月。估计3年和5年总生存率分别为62.3%（95%CI=27.8-84.0）和31.2%（95%CI=1.7-71.7）。
结论
对于部分选择的PDAC患者，肺转移瘤切除术后的结果良好。
Zotero 插件